From nanoparticle-protein to nanoparticle-complement interactions
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Characterization and Applications of Magnetic Nanoparticles
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Diffusion
2. Enzyme entrapment in liposomes10.1016/0014-5793(71)80109-6 ↗
3. Fate of protein-containing liposomes injected into rats. an approach to the treatment of storage disease10.1111/j.1432-1033.1972.tb19710.x ↗
4. The effect of serum protein fractions on liposome-cell interaction in cultured cells and the perfused liver10.1016/0304-4165(77)90204-5 ↗
5. Interaction of liposomes with blood plasma proteins
6. Interaction of C-reactive protein and complement with liposomes10.4049/jimmunol.122.4.1185 ↗
7. Liposome uptake by human leukocytes. Enhancement of entry mediated by human serum and aggregated immunoglobulin10.1016/0304-4165(81)90337-8 ↗
8. B-2-glycoprotein I (apolipoprotein H) interaction with phospholipid vesicles10.1016/0020-711X(84)90168-X ↗
9. Interaction of liposomes with serum proteins10.1016/0009-3084(86)90079-4 ↗
10. Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol-rich liposomes10.1016/0014-5793(88)81372-3 ↗
11. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes10.1016/0005-2736(89)90307-6 ↗
12. Complement-dependent phagocytosis of liposomes by macrophages. Suppressive effects of stealth lipids10.1016/S0006-291X(05)80266-9 ↗
13. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes10.4049/jimmunol.146.12.4234 ↗
14. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes10.1016/S0021-9258(19)37026-7 ↗
15. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system — The concept of tissue specificity10.1016/S0169-409X(97)00131-2 ↗
16. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups10.1023/A:1011054123304 ↗
17. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis10.1002/elps.11501401214 ↗
18. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonisation but permits the activity of dysopsonins in the serum10.1016/0167-4889(93)90137-E ↗
19. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) on the core composition on phagocytic uptake and plasma protein adsorption10.1016/S0927-7765(99)00156-3 ↗
20. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonisation and protein-binding properties10.1016/S0163-7827(03)00033-X ↗
21. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective10.1146/annurev-pharmtox-010611-134623 ↗
22. Dawson, Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts
23. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
24. Current understanding of biological identity at the nanoscale and future prospects10.1038/s41565-021-00860-0 ↗
25. The need for improved methodology in protein corona analysis10.1038/s41467-021-27643-4 ↗
26. Effect of adsorbed proteins on the wettability of hydrophilic and hydrophobic solids10.1038/196476a0 ↗
27. Adsorption of proteins out of plasma and solutions in narrow spaces10.1016/0021-9797(86)90042-1 ↗
28. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance10.1016/S0014-5793(02)03710-9 ↗
29. Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation10.1021/ar1001389 ↗
30. Heterogeneity in nanoparticles influences biodistribution and targeting10.2217/nnm.13.70 ↗
31. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome10.1016/j.jconrel.2015.11.021 ↗
32. Intrinsic and dynamic heterogeneity of nonlamellar lyotropic liquid crystalline nanodispersions10.1021/acsnano.3c09231 ↗
33. Nanomedicine—lipoprotein interactions10.1038/s44222-025-00291-9 ↗
34. Interplay of protein corona and immune cells controls blood residency of liposomes10.1038/s41467-019-11642-7 ↗
35. Person-specific biomolecular coronas modulate nanoparticle interactions with immune cells in human blood10.1021/acsnano.0c06679 ↗
36. An overview of nanoparticle protein corona literature
37. In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles10.1021/acsnano.5b03300 ↗
38. Biological identity of nanoparticles in vivo: clinical implications of the protein corona10.1016/j.tibtech.2016.08.011 ↗
39. Personalized protein coronas: a “key” factor at the nanobiointerface10.1039/C4BM00131A ↗
40. Opsonins and dysopsonins of nanoparticles: facts, concepts, and methodological guidelines10.3389/fimmu.2020.567365 ↗
41. Opsonins and dysopsonins: an overview10.1016/S0076-6879(86)32015-9 ↗
42. Serum factors that regulate phagocytosis of liposomes by Kupffer cells10.1042/bst021128s ↗
43. Clustrin in the protein corona plays a key role in the stealth effect of nanoparticles against phagocytes10.1016/j.bbrc.2016.10.121 ↗
44. C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly(2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes10.1021/acsnano.8b01806 ↗
45. The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses10.1124/jpet.119.258012 ↗
46. Protein corona: friend or foe? Co-opting serum proteins for nanoparticle delivery10.1016/j.addr.2022.114635 ↗
47. Species differences in opsonisation and phagocyte recognition of preclinical poly-2-alkyl-2-oxazoline-coated nanoparticles10.1038/s41467-025-57648-2 ↗
48. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo10.1038/nnano.2016.269 ↗
49. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®)10.3109/08982100009031112 ↗
50. Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts10.1021/acsnano.4c05087 ↗
51. Optimized enzyme-linked immunosorbent assay for anti-PEG antibody detection in healthy donors and patients treated with PEGylated liposomal doxorubicin10.1021/acs.molpharmaceut.4c00278 ↗
52. Influence of poly(ethylene glycol) grafting and polymer length on liposomes: relating plasma circulation lifetimes to protein binding
53. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b. Implications for phagocytoses and antibody production10.1093/infdis/153.4.682 ↗
54. Utilization of complement receptors in immune–microbe interaction10.1002/1873-3468.13743 ↗
55. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells10.1016/0167-4889(92)90230-9 ↗
56. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery10.1038/s41596-022-00755-x ↗
57. Combination of physicochemical tropism and affinity moiet targeting of lipid nanoparticles enhances organ targeting
58. The endothelial glycocalyx: emerging concepts in pulmonary edema and acute lung injury10.1213/ANE.0b013e3182975b85 ↗
59. Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents10.1016/0169-409X(95)00043-7 ↗
60. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer10.1038/gt.2008.60 ↗
61. Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system10.1021/acsnano.4c06286 ↗
62. Lung-specific mRNA delivery by ionisable lipids with defined structure-function relationship and unique protein corona feature
63. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function10.1038/s41467-023-39768-9 ↗
64. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL10.1172/JCI26206 ↗
65. A guide to complement biology, pathology and therapeutic opportunity10.1038/s41577-023-00926-1 ↗
66. Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities10.1016/j.addr.2020.04.012 ↗
67. Nanometer- and angstrom-scale characteristics that modulate complement responses to nanoparticles10.1016/j.jconrel.2022.09.039 ↗
68. Activation of the complement system by nanoparticles and strategies for complement inhibition10.1016/j.ejpb.2023.11.006 ↗
69. Perspectives on complement and phagocytic cell responses to nanoparticles: from fundamentals to adverse reactions10.1016/j.jconrel.2023.02.022 ↗
70. Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology10.1016/j.nantod.2022.101479 ↗
71. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation
72. Primate erythrocyte-immune complex-clearing mechanism10.1172/JCI110764 ↗
73. CR1 and CR1-like: the primate immune adherence receptors10.1034/j.1600-065X.2001.1800109.x ↗
74. Erythrocyte complement receptor 1 (CR1) expression level is not associated with polymorphisms in the promoter or 3’ untranslated regions of the CR1 gene10.1111/j.1744-313X.2005.00552.x ↗
75. Pitfalls in complement analysis: A systematic literature review of assessing complement activation10.3389/fimmu.2022.1007102 ↗
76. The complotype: dictating risk for inflammation and infection10.1016/j.it.2012.06.001 ↗
77. Common polymorphism in C3, Factor B, and Factor H collaborate to determine systemic complement activity and disease risk
78. Age and sex-associated changes of complement activity and complement levels in a healthy caucassian population10.3389/fimmu.2018.02664 ↗
79. Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein
80. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation10.1111/jth.13208 ↗
81. The role of antibody in the activation of the alternative pathway
82. Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles10.1038/s41565-018-0344-3 ↗
83. MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked10.1038/srep31877 ↗
84. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity10.1182/blood.2020005959 ↗
85. Janeway · 2001
86. Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals10.1038/s41467-025-57947-8 ↗
87. The C3 convertase of the alternative pathway of human complement. Enzymatic properties of the bimolecular proteinase10.1042/bj2350723 ↗
88. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation10.4049/jimmunol.0902214 ↗
89. Tunable complement activation by particles with variable size and Fc density10.1142/S1793984413410018 ↗
90. Unravelling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces10.1021/acs.nanolett.9b02220 ↗
91. The human C1q globular domain: structure and recognition of non-immune self ligands10.3389/fimmu.2011.00092 ↗
92. C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14–26 of the human C1qA chain in a sequence independent manner10.1016/S0005-2736(99)00013-9 ↗
93. Complement activation and protein adsorption by carbon nanotubes10.1016/j.molimm.2005.02.006 ↗
94. Characterization of the oligomer structure of recombinant human mannan-binding lectin10.1074/jbc.M412472200 ↗
95. Mannan-binding lectin: structure, oligomerization, and flexibility studies by atomic force microscopy10.1016/j.jmb.2009.05.083 ↗
96. Structural insights into the recognition properties of human ficolins10.1159/000233475 ↗
97. The role of nanometer-scaled ligand patterns in polyvalent binding by large mannan-binding lectin oligomers10.4049/jimmunol.1103012 ↗
98. Complement activation by PEGylated single-wall carbon nanotubes is independent of C1q and alternative pathway turnover10.1016/j.molimm.2008.05.020 ↗
99. Single-walled carbon nanotube surface control of complement recognition and activation10.1021/nn3055175 ↗
100. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum10.1186/s12989-014-0064-2 ↗